Melissa Rikal, MSN, FNP-BC, AOCNP

Melissa Rikal, FNP-BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in patients with metastatic breast cancer, particularly as a mechanism of resistance to aromatase inhibitor treatment.